NCT03541356View on ClinicalTrials.gov

Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

June 11, 2019

Study Completion Date

June 11, 2019

Conditions
Parkinson's Disease
Interventions
COMBINATION_PRODUCT

Placebo

Delivered via the I231 POD (Precision Olfactory Delivery) device

COMBINATION_PRODUCT

L-dopa 35 mg

Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril

COMBINATION_PRODUCT

L-dopa 70mg

Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril

COMBINATION_PRODUCT

L-dopa 140 mg

Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril

COMBINATION_PRODUCT

L-dopa 70mg/carbidopa 7mg

Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril

Trial Locations (5)

2031

The Brain and Mind Centre / Scientia Clinical Research, Sydney

6009

Perron Institute, Perth

Unknown

Q-Pharm, Brisbane

The Mater Hospital, Brisbane

The Alfred Hospital, Melbourne

Sponsors
All Listed Sponsors
lead

Impel Pharmaceuticals

INDUSTRY